Domain Parters Vii L P

disclosed that they own a 4.2% stake in Esperion Therapeutics Inc (NASDAQ:ESPR) in a Schedule 13D/A disclosure that was filed with the Securities and Exchange Commission on Monday, January 29th. The investor owns 1,101,080 shares of the stock worth approximately $80,819,272. The reporting parties listed on the disclosure included Domain Partners VII, LP, DP VII Associates, LP and Domain Associates, LLC. The filing is available through the SEC website at this link.

A number of other hedge funds and other institutional investors have also bought and sold shares of ESPR. Voya Investment Management LLC lifted its holdings in shares of Esperion Therapeutics by 12.7% during the 2nd quarter. Voya Investment Management LLC now owns 7,148 shares of the biopharmaceutical company’s stock worth $331,000 after acquiring an additional 806 shares during the period. TIAA CREF Investment Management LLC lifted its holdings in shares of Esperion Therapeutics by 3.0% during the 2nd quarter. TIAA CREF Investment Management LLC now owns 39,074 shares of the biopharmaceutical company’s stock worth $1,808,000 after acquiring an additional 1,148 shares during the period. Alliancebernstein L.P. lifted its holdings in shares of Esperion Therapeutics by 5.3% during the 2nd quarter. Alliancebernstein L.P. now owns 30,070 shares of the biopharmaceutical company’s stock worth $1,392,000 after acquiring an additional 1,500 shares during the period. Parametric Portfolio Associates LLC lifted its holdings in shares of Esperion Therapeutics by 3.4% during the 2nd quarter. Parametric Portfolio Associates LLC now owns 50,420 shares of the biopharmaceutical company’s stock worth $2,333,000 after acquiring an additional 1,658 shares during the period. Finally, Russell Investments Group Ltd. lifted its holdings in shares of Esperion Therapeutics by 8.3% during the 3rd quarter. Russell Investments Group Ltd. now owns 25,072 shares of the biopharmaceutical company’s stock worth $1,257,000 after acquiring an additional 1,913 shares during the period. 92.98% of the stock is owned by hedge funds and other institutional investors.

Shares of Esperion Therapeutics Inc (ESPR) traded down $1.48 during midday trading on Monday, reaching $73.40. 311,914 shares of the company’s stock traded hands, compared to its average volume of 580,531. Esperion Therapeutics Inc has a 1 year low of $10.82 and a 1 year high of $82.18. The firm has a market cap of $1,900.00, a PE ratio of -10.66 and a beta of 2.73.

Esperion Therapeutics (NASDAQ:ESPR) last announced its quarterly earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($1.86) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.79) by ($0.07). During the same quarter in the previous year, the business posted ($0.77) EPS. equities research analysts expect that Esperion Therapeutics Inc will post -7.3 earnings per share for the current fiscal year.

In other Esperion Therapeutics news, Director Nicole Vitullo sold 9,326 shares of the company’s stock in a transaction that occurred on Wednesday, December 6th. The shares were sold at an average price of $53.85, for a total value of $502,205.10. Following the completion of the transaction, the director now directly owns 2,472 shares in the company, valued at approximately $133,117.20. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Corporate insiders own 32.50% of the company’s stock.

A number of research firms recently issued reports on ESPR. Stifel Nicolaus reiterated a “buy” rating and set a $70.00 price objective on shares of Esperion Therapeutics in a research report on Wednesday, October 4th. Needham & Company LLC upgraded shares of Esperion Therapeutics from a “buy” rating to a “strong-buy” rating and upped their price objective for the stock from $72.00 to $81.00 in a research report on Thursday, December 14th. Northland Securities reiterated a “buy” rating and set a $72.00 price objective on shares of Esperion Therapeutics in a research report on Wednesday, October 4th. BidaskClub upgraded shares of Esperion Therapeutics from a “hold” rating to a “buy” rating in a research report on Saturday, December 16th. Finally, Credit Suisse Group began coverage on shares of Esperion Therapeutics in a research report on Wednesday, January 17th. They set an “outperform” rating and a $103.00 price objective for the company. Six equities research analysts have rated the stock with a hold rating, eight have issued a buy rating and two have assigned a strong buy rating to the company. The stock has a consensus rating of “Buy” and an average price target of $77.23.

TRADEMARK VIOLATION NOTICE: “Esperion Therapeutics Inc (ESPR) Stake Owned by Domain Parters Vii L P” was reported by Watch List News and is the property of of Watch List News. If you are accessing this article on another domain, it was stolen and republished in violation of United States & international copyright & trademark legislation. The legal version of this article can be read at https://www.watchlistnews.com/esperion-therapeutics-inc-espr-stake-owned-by-domain-parters-vii-l-p/1831165.html.

Esperion Therapeutics Profile

Esperion Therapeutics, Inc is a lipid management company. The Company is a late-stage pharmaceutical company focused on developing and commercializing once-daily, oral therapies for the treatment of patients with elevated low-density lipoprotein cholesterol (LDL-C). With a targeted mechanism of action, bempedoic acid, the Company’s lead product candidate, is an orally available, once-daily adenosine triphosphate (ATP)-citrate lyase (ACL) inhibitor that reduces cholesterol biosynthesis and lowers elevated levels of LDL-C by up-regulating the LDL receptor, but with reduced potential for muscle-related side effects.

Institutional Ownership by Quarter for Esperion Therapeutics (NASDAQ:ESPR)

Receive News & Ratings for Esperion Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Esperion Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.